FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment of calves with Emdocam 20 minutes before dehorning reduces post-operative pain.
Estonian: Vasikate ravi Emdocamiga 20 minutit enne sarvede eemaldamist vähendab operatsioonijärgset valu.
English: In case of overdose, symptomatic treatment should be initiated.
Estonian: Üleannustamise korral alustada sümptomaatilist ravi.
English: 5 days.
Estonian: 5 päeva.
English: The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Estonian: Ravimi omaduste kokkuvõtte lõigus 6.1 loetletud abiained on kas lubatud ained, mille kohta ei ole komisjoni määruse (EL) nr 37/2010 lisa tabeli 1 kohaselt jääkide piirnormid vajalikud, või neid abiaineid ei loeta selles ravimis kasutatuna määruse (EÜ) number 470/2009 rakendusalasse kuuluvaks.
English: Not authorised for use in horses producing milk for human consumption.
Estonian: Ei ole lubatud kasutamiseks lakteerivatel hobustel, kelle piima tarvitatakse inimtoiduks.
English: Meloxicam in Emdocam 20 mg/ml solution for injection for cattle, pigs and horses is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Estonian: Emdocam 20 mg/ml süstelahuse veistele, sigadele ja hobustele toimeaine meloksikaam on lubatud aine, nagu on kirjeldatud komisjoni määruse (EL) nr 37/2010 lisa tabelis 1:
English: MANUFACTURER´S BATCH NUMBER
Estonian: TOOTJAPOOLNE PARTII NUMBER
English: 20 μg/kg 65 μg/kg 65 μg/kg
Estonian: 20 µg/kg 65 µg/kg 65 µg/kg
English: Milk: 5 days
Estonian: piimale: 5 päeva.
English: 150 mg For the full list of excipients, see section 6.1.
Estonian: 150 mg Abiainete täielik loetelu on esitatud punktis 6.1.
English: Name and address of the manufacturer responsible for batch release Produlab Pharma bv
Estonian: Ravimipartii kasutamiseks vabastamise eest vastutava tootja nimi ja aadress Produlab Pharma bv
English: Any unused medicines should not be disposed of via wastewater or household waste.
Estonian: Kasutamata jäänud ravimeid ega jäätmematerjali ei tohi ära visata kanalisatsiooni kaudu ega koos majapidamisprügiga.
English: 15 μg/kg Milk
Estonian: 15 µg/kg Piim
English: To a minor extent it also inhibits collagen-induced thrombocyte aggregation.
Estonian: Vähemal määral pärsib see ka kollageeni poolt esile kutsutud trombotsüütide agregatsiooni.
English: Each vial is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.
Estonian: Iga viaal on suletud bromobutüülkummist punnkorgiga ja tihendatud alumiiniumkattega.
English: Horses: I.V.
Estonian: Hobune: i.v.
English: EXP {month/year} Once broached, use by…
Estonian: EXP {kuu/aasta} Pärast pakendi avamist kasutada kuni...
English: THE WORDS "FOR ANIMAL TREATMENT ONLY"
Estonian: MÄRGE “AINULT VETERINAARSEKS KASUTAMISEKS”
English: Emdoka bvba J. Lijsenstraat 16 B-2321 Hoogstraten Belgium
Estonian: Emdoka bvba J. Lijsenstraat 16 B-2321 Hoogstraten Belgia
English: Pack size of 1 colourless Type I glass vial containing 50 ml, 100 ml or 250 ml.
Estonian: Pakendi suurus: 1 värvitust I tüüpi klaasist viaaliga, iga viaal sisaldab 50 ml, 100 ml või 250 ml.
English: Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant medicinal products.
Estonian: Mitte manustada samaaegselt glükokortikosteroidide, muude mittesteroidsete põletikuvastaste ravimite ega hüübimisvastaste ravimitega.
English: ChemVet dk A/S A.C. Illums Vej 6
Estonian: ChemVet dk A/S A.C.
English: SC Altius SRL Str Iancu Capitanu nr 38 Ap 1 Sector 2, Bucuresti - RO Tel: + 40 021 310 88 80
Estonian: Str Iancu Capitanu nr 38 Ap 1 Sector 2, Bucuresti - RO Tel: + 40 021 310 88 80
English: Emdocam alone will not provide adequate pain relief during the dehorning procedure.
Estonian: Sarvede eemaldamise operatsiooni käigus ei vähenda Emdocam üksi piisavalt valu.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals, including isolated reports treated).
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10,000-st ravitud loomast) - väga harv (vähem kui 1-l loomal 10,000-st ravitud loomast, kaasaarvatud üksikjuhud).
English: H-7020 Dunaföldvár Tel.: +36 75 542 940
Estonian: HU-7020 Dunaföldvár Tel.: +36 75 542 940
English: Cattle: S.C., I.V.
Estonian: Veis: s.c, i.v.
English: After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmaxvalues of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Estonian: Pärast ühekordset subkutaanset annust 0,5 mg meloksikaami/kg saavutati noorveistel ja lakteerivatel lehmadel Cmax väärtused 2,1 µg/ml ja 2,7 µg/ml vastavalt 7,7 tunni ja 4 tunni pärast.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja viaalil pärast EXP. Kõlblikkusaeg viitab selle kuu viimasele päevale.
English: People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Estonian: Inimesed, kes on mittesteroidsete põletikuvastaste ravimite suhtes ülitundlikud, peaksid kokkupuudet veterinaarravimiga vältima.
English: For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo-skeletal disorders, a suitable oral therapy containing meloxicam, administered in accordance with label recommendations, may be used for continuation of treatment.
Estonian: Põletiku ja valu leevendamiseks ägedate ja krooniliste lihas-skeleti häirete korral võib ravi jätkamiseks kasutada meloksikaami sisaldavat sobivat suukaudset ravimit, manustades seda etiketil märgitud viisil.
English: After two intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.9 µg/ml was reached after 1 hour in pigs.
Estonian: Pärast kaht intramuskulaarset annust 0,4 mg meloksikaami/kg saavutati sigadel Cmax väärtus 1,9 µg/ml 1 tunni pärast.
English: Meloxicam Meloxicam Bovine, caprine, porcine, rabbit,
Estonian: Meloksikaam Meloksikaam Veised, kitsed, sead, küülik, hobuslased
English: THE WORDS "KEEP OUT OF SIGHT AND REACH OF CHILDREN"
Estonian: MÄRGE "HOIDA LASTE EEST VARJATUD JA KÄTTESAAMATUS KOHAS"
English: For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Estonian: Poegimisjärgse sepsise ja tokseemia (mastiidi-metriidi-agalaktia sündroomi) täiendavaks raviks koos sobiva antibiootikumiraviga.
English: Shelf-life after first opening of the container: 28 days.
Estonian: Kõlblikkusaeg pärast viaali esmakordset avamist: 28 päeva.
English: Cattle: meat and offal: 15 days; milk: 5 days
Estonian: lihale ja söödavatele kudedele: 15 päeva; piimale: 5 päeva.
English: Ethanol (96%) Poloxamer 188
Estonian: Etanool (96%)
English: Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects.
Estonian: Meloksikaam on oksikaamide rühma kuuluv mittesteroidne põletikuvastane ravim, mille põletikuvastane, antieksudatiivne, valuvaigistav ja palavikuvastane toime on tingitud prostaglandiini sünteesi inhibeerimisest.
English: Do not use in pregnant and lactating mares.
Estonian: mitte kasutada tiinetel ja lakteerivatel märadel.
English: Once broached, use by…
Estonian: Pärast pakendi avamist kasutada kuni...
English: 4.7 Use during pregnancy, lactation or lay Cattle and pigs:
Estonian: 4.7 Kasutamine tiinuse, laktatsiooni või munemise perioodil
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial label for 100 ml and 250 ml
Estonian: NÕUDED, MIS PEAVAD OLEMA VAHETUL SISEPAKENDIL 100 ml ja 250 ml viaalide etikett
English: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Estonian: Põletiku ja valu leevendamiseks nii ägedate kui ka krooniliste lihas-skeleti kahjustuste korral.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE OUTER CARTON - 50, 100 or 250 ml vials
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED KARP - 50 ml, 100 ml või 250 ml viaalid
English: Pregnancy and lactation Cattle and pigs:
Estonian: Tiinus ja laktatsioon: Veistel ja sigadel:
English: Overdose (symptoms, emergency procedures, antidotes): In case of overdose, symptomatic treatment should be initiated.
Estonian: Üleannustamine (sümptomid, esmaabi, antidoodid)
English: Horses: Meat and offal:
Estonian: Hobune: Lihale ja söödavatele kudedele:
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label for 50 ml
Estonian: MIINIMUMNÕUDED ANDMETE OSAS, MIS PEAVAD OLEMA ÄRA MÄRGITUD VÄIKESEL VAHETUL SISEPAKENDIL
English: Horses: meat and offal: 5 days.
Estonian: Hobune: lihale ja söödavatele kudedele: 5 päeva.
English: Ethanol (96%) 150 mg Clear yellow solution for injection.
Estonian: 150 mg Selge kollane süstelahus.
English: Pharmacologically active substance
Estonian: Farmakoloogilisetoi mega aine
English: To obtain adequate pain relief during surgery, co-medication with an appropriate analgesic is needed.
Estonian: Piisavaks valu leevendamiseks operatsiooni käigus on tarvis samaaegselt kasutada sobivat valuvaigistit.
English: NL-4941 SJ Raamsdonksveer The Netherlands
Estonian: Partii vabastamise eest vastutav tootja Produlab Pharma bv NL-4941 SJ Raamsdonksveer Holland
English: Emdocam 20 mg/ml solution for injection for cattle, pigs and horses meloxicam
Estonian: Emdocam 20 mg/ml süstelahus veistele, sigadele ja hobustele meloksikaam
English: Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
Estonian: Emdocam, 20 mg/ml süstelahus veistele, sigadele ja hobustele
English: Do not use in pregnant or lactating mares.
Estonian: Mitte kasutada tiinetel ega lakteerivatel märadel.
English: Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
Estonian: Manustada subkutaanselt või intravenoosselt üks kord annuses 0,5 mg meloksikaami 1 kg kehamassi kohta (st 2,5 ml 100 kg kehamassi kohta), vajaduse korral kombineeritult antibiootikumiraviga või suukaudse rehüdratsioonraviga.
English: MRL Target tissues
Estonian: SC Altius SRL
English: Single intravenous injection at a dose of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).
Estonian: Manustada üks kord intravenoosselt annuses 0,6 mg meloksikaami 1 kg kehamassi kohta (st 3,0 ml 100 kg kehamassi kohta).
English: Shelf-life of the veterinary medicinal product as packaged for sale: 3 years Shelf-life after first opening the immediate packaging: 28 days
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg: 3 aastat.
English: Excipient:
Estonian: Siga:
English: Single intramuscular injection at a dose of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
Estonian: Manustada üks kord intramuskulaarselt annuses 0,4 mg meloksikaami 1 kg kehamassi kohta (st 2,0 ml 100 kg kehamassi kohta), vajaduse korral kombineeritult antibiootikumiraviga.
English: Cattle: Meat and offal:
Estonian: Lihale ja söödavatele kudedele:
English: meat and offal: 5 days.
Estonian: lihale ja söödavatele kudedele: 5 päeva.
English: Emdocam 20 mg/ml solution for injection for cattle, pigs and horses NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Estonian: MÜÜGILOA HOIDJA NING, KUI NEED EI KATTU, RAVIMIPARTII VABASTAMISE EEST VASTUTAVA TOOTMISLOA HOIDJA NIMI JA AADRESS
English: 4.11 Withdrawal periods
Estonian: 4.11 Keeluaeg (-ajad) Veis:
English: Muscle Liver Kidney
Estonian: Lihaskude Maks Neer
English: PACKAGE LEAFLET FOR:
Estonian: KEELUAEG Veis:
English: DD.MM.YYYY
Estonian: DD/MM/AAAA
English: No entry Anti-inflammatory agents/Non-steroidal anti-inflammatory agents
Estonian: Põletikuvastased ravimid / mittesteroidsed põletikuvastased ravimid
English: IM
Estonian: A.
English: The marketing authorisation holder is Pacira Limited.
Estonian: Müügiloa hoidja on Pacira Limited.
English: The European Commission granted a marketing authorisation valid throughout the European Union for DepoCyte on 11 July 2001.
Estonian: Euroopa Komisjon andis DepoCyte müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11. juulil 2001.
English: The main measure of effectiveness was the number of patients who responded to treatment.
Estonian: Efektiivsuse põhinäitaja oli ravivastusega patsientide arv.
English: DepoCyte cytarabine
Estonian: DepoCyte tsütarabiin
English: Pyrimidine is part of the genetic material of cells (DNA and RNA).
Estonian: Pürimidiin kuulub rakkude geneetilise materjali (DNA ja RNA) hulka.
English: As a result, cytarabine slows down the growth of tumour cells and eventually kills them.
Estonian: Selle tulemusena aeglustab tsütarabiin kasvajarakkude kasvu ja lõpuks hävitab need.
English: This document is a summary of the European Public Assessment Report (EPAR) for DepoCyte.
Estonian: Käesolev dokument on ravimi DepoCyte Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee decided that DepoCyte's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et DepoCyte kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: DepoCyte helps to control the symptoms of the disease.
Estonian: DepoCyte aitab haigussümptomeid ohjeldada.
English: In the main study, 72% of the patients who received DepoCyte responded to treatment (13 out of 18), compared with 18% of those who received the standard formulation of cytarabine (3 out of 17).
Estonian: Põhiuuringus tekkis ravivastus 72%-l DepoCytet saanud patsiendist (13 patsienti 18st) ja 18%-l tsütarabiini standardset ravimvormi saanud patsiendist (3 patsiendist 17st).
English: This is then followed by maintenance doses of 50 mg every four weeks for a further four doses.
Estonian: Seejärel manustatakse veel neljal korral 50 mg säilitusannus iga nelja nädala järel.
English: Other information about DepoCyte:
Estonian: Muu teave DepoCyte kohta
English: These symptoms mainly affect the nerves, and include pain, fits, headache, problems walking, memory problems, incontinence and unusual sensations.
Estonian: Need sümptomid mõjutavad peamiselt närve, tekitavad valu, krampe, peavalu, raskusi kõndimisel, mäluhäireid, uriinipidamatust ja vääraistinguid.
English: For more information about treatment with DepoCyte, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate DepoCytega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: DepoCyte is first given as a 50-mg injection every two weeks for the first five doses, followed by a further 50 mg four weeks later.
Estonian: DepoCytet manustatakse kõigepealt esimese viie annuse korral 50 mg süstina iga kahe nädala järel ning pärast seda manustatakse neli nädalat hiljem veel 50 mg annus.
English: Cytarabine is an analogue of pyrimidine.
Estonian: Tsütarabiin on pürimidiini analoog.
English: The dose can be decreased to 25 mg if the patient shows signs of damage to the nerves (such as headache, abnormal vision, muscle weakness or pain).
Estonian: Annust võib vähendada kuni 25 mg-ni, kui patsiendil ilmnevad närvikahjustuse nähud (näiteks peavalu, nägemishäired, lihaste nõrkus või valu).
English: DepoCyte should not be given to people who may be hypersensitive (allergic) to cytarabine or any of the other ingredients.
Estonian: DepoCytet ei tohi kasutada patsiendid, kes võivad olla tsütarabiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: However, there was no difference between the two medicines in how long the patients lived without their nerve disease getting worse.
Estonian: Siiski ei täheldatud kahe ravimi erinevust närvihaiguse progresseerumiseni kulunud aja osas.
English: The active substance in DepoCyte, cytarabine (also known as ara-C), is an anticancer medicine that has been used since the 1970s.
Estonian: DepoCyte toimeaine tsütarabiin (teise nimetusega ara-C) on vähiravim, mida on kasutatud alates 1970. aastatest.
English: In the body, cytarabine takes the place of pyrimidine and interferes with the enzymes involved in the production of new DNA.
Estonian: Tsütarabiin asub organismis pürimidiini asemele ja häirib uue DNA moodustamises osalevate ensüümide toimet.
English: What is the risk associated with DepoCyte?
Estonian: Mis riskid DepoCytega kaasnevad?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DepoCyte.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: It must not be used in patients who have an active infection in the meninges.
Estonian: Ravimit ei tohi kasutada ajukelmete aktiivse põletikuga patsiendid.
English: DepoCyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
Estonian: DepoCyte on süstesuspensioon, mis sisaldab toimeainena 50 mg tsütarabiini.
English: The CHMP noted that DepoCyte had shown effectiveness in lymphomatous meningitis when compared with the standard formulation of cytarabine, and that it could improve patients' quality of life because fewer intrathecal injections are needed.
Estonian: Inimravimite komitee märkis, et DepoCyte on osutunud lümfomatoosse meningiidi ravis tsütarabiini standardsest ravimvormist efektiivsemaks ja et DepoCyte tõstab patsientide elukvaliteeti intratekaalsete süstide väiksema vajaduse tõttu.
English: DepoCyte should only be given by a doctor who has experience in the use of anticancer medicines.
Estonian: Ravi DepoCytega võib määrata üksnes vähiravimite kasutamise kogemusega arst.
English: For the full list of all side effects reported with DepoCyte, see the Package Leaflet.
Estonian: DepoCyte kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: A patient was classified as a ‘responder' if they had no cancer cells in the spinal fluid after treatment and if their symptoms had not got worse after four weeks.
Estonian: Ravivastus loeti tekkinuks, kui patsiendi seljaaju vedelikus puudusid vähirakud pärast ravi ja kui patsiendi haigus ei olnud pärast nelja nädalat progresseerunud.
English: What is DepoCyte?
Estonian: Mis on DepoCyte?
English: DepoCyte is a ‘depot' injection (a type of injection where the medicine is prepared so that it is absorbed by the body very slowly).
Estonian: DepoCytet süstitakse depoosüstina (süsti liik, mille korral ravim on valmistatud nii, et see imendub organismi väga aeglaselt).
English: In DepoCyte, cytarabine is contained in liposomes (small fatty particles), from which the medicine is released slowly.
Estonian: DepoCyte sisaldab tsütarabiini liposoomides (väikesed rasvaosakesed), millest ravim aeglaselt vabaneb.
English: Why has DepoCyte been approved?
Estonian: Miks DepoCyte heaks kiideti?
English: The study also looked at how long the patients lived without their nerve disease getting worse.
Estonian: Uuringus jälgiti patsientide elulemust närvihaiguse süvenemiseni.
English: The most common side effects with DepoCyte (seen in more than 1 treatment cycle in 10) are headache, arachnoiditis (inflammation of one of the membranes protecting the spine and the brain), confusion, nausea (feeling sick), vomiting, diarrhoea, pyrexia (fever), weakness and thrombocytopenia (low blood platelet counts).To minimise the symptoms of arachnoiditis, patients should receive dexamethasone by mouth or by injection at the same time as DepoCyte and must be closely monitored.
Estonian: DepoCyte kõige sagedamad kõrvalnähud (esinenud enam kui 1 ravitsükli jooksul 10st) on peavalu, arahnoidiit (selja- ja peaaju teatud kelme ehk ämblikuvõrkkesta põletik), segasus, iiveldus, oksendamine, kõhulahtisus, palavik, nõrkus ja trombotsütopeenia (vereliistakute vähesus).
English: It is a cytotoxic (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the ‘anti-metabolite' group.
Estonian: See on antimetaboliitide rühma kuuluv tsütotoksiline aine (ravim, mis hävitab jagunevaid rakke, näiteks vähirakke).
English: The full EPAR for DepoCyte can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst DepoCyte kohta on siin.
English: What benefit has DepoCyte shown during the studies?
Estonian: Milles seisneb uuringute põhjal DepoCyte kasulikkus?
English: How has DepoCyte been studied?
Estonian: Kuidas DepoCytet uuriti?
English: The medicine must be injected ‘intrathecally' (directly into the spinal fluid in the space that surrounds the spinal cord and the brain).
Estonian: Ravimit peab süstima intratekaalselt (otse seljaaju vedelikku selja- ja peaaju ümbritsevate kelmete vahele).
English: The patient should also receive dexamethasone (a steroid) to help control some of the medicine's side effects.
Estonian: Ravimi mõningate kõrvalnähtude ärahoidmiseks peaks patsient saama ka deksametasooni (steroidi).
English: How is DepoCyte used?
Estonian: Kuidas DepoCytet kasutatakse?
English: What is DepoCyte used for?
Estonian: Milleks DepoCytet kasutatakse?
English: DepoCyte has been compared with a standard formulation of cytarabine in one main study involving 35 patients with lymphomatous meningitis.
Estonian: Põhiuuringus, milles osales 35 lümfomatoosse meningiidiga patsienti, võrreldi DepoCytet tsütarabiini standardse ravimvormi kasutamisega.
English: This is a condition in which cells from a lymphoma (a tumour in the lymphatic system) have spread to the spinal fluid and the meninges (the membranes that surround the brain and spinal cord).
Estonian: DepoCytet kasutatakse lümfomatoosse meningiidi raviks: see on seisund, mille korral lümfoomirakud (lümfisüsteemi kasvaja) on tunginud seljaaju vedelikku ja ajukelmetesse (pea- ja seljaaju ümbritsevatesse kelmetesse).
English: 28 x 1 tablets
Estonian: Blister (polüamiid/alumiinium/PVC) 28 x 1 tabletti
English: Dose adjustments might be necessary in these patients.
Estonian: Nendel patsientidel võib olla vajalik annust kohandada.
English: Gabapentin - Respiratory depression without concomitant opioid use (EPITT no 18814)
Estonian: Gabapentiin - respiratoorne depressioon ilma samaaegse opioidravita (EPITT nr 18 814)
English: Adopted at the 6-9 June 2017 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 6.-9. juuni 2017 koosolekul
English: - if you have nervous system disorders, respiratory disorders, or you are more than 65 years old, your doctor may prescribe you a different dosing regimen
Estonian: − kui teil on närvisüsteemi häired, hingamishäired või kui olete üle 65-aastane, võib arst teile määrata teistsuguse annustamisskeemi
English: Contact your doctor immediately if you experience any of the following symptoms after taking this medicine as they can be serious:
Estonian: Pöörduge otsekohe oma arsti poole, kui teil esineb ravimi võtmise järel mis tahes järgmisi sümptomeid, sest need võivad olla rasked: